Európai Unió - szlovén - EMA (European Medicines Agency)

accord healthcare s.l.u. - leuprorelin mesilate - prostatične neoplazme - endokrini terapija - camcevi is indicated for the treatment of hormone dependent advanced prostate cancer and for the treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy.

Európai Unió - szlovén - EMA (European Medicines Agency)

ferring pharmaceuticals a/s - degareliks - prostatične neoplazme - endokrini terapija - firmagon is a gonadotrophin releasing hormone (gnrh) antagonist indicated:- for treatment of adult male patients with advanced hormone-dependent prostate cancer. - for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. - as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Európai Unió - szlovén - EMA (European Medicines Agency)

accord healthcare s.l.u. - degarelix acetate - prostatične neoplazme - other hormone antagonists and related agents - degarelix accord is a gonadotrophin releasing hormone (gnrh) antagonist indicated:for treatment of adult male patients with advanced hormone-dependent prostate cancer. for treatment of high-risk localised and locally advanced hormone dependent prostate cancer in combination with radiotherapy. as neo-adjuvant treatment prior to radiotherapy in patients with high-risk localised or locally advanced hormone dependent prostate cancer.

Szlovénia - szlovén - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

astellas pharma d.o.o. - levprorelin - prašek in vehikel za raztopino za injiciranje - levprorelin 41,7 mg / 1 brizga - levprorelin

Szlovénia - szlovén - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

astellas pharma d.o.o. - levprorelin - prašek in vehikel za raztopino za injiciranje - levprorelin 20,87 mg / 1 brizga - levprorelin

Szlovénia - szlovén - JAZMP (Javna agencija RS za zdravila in medicinske pripomočke)

astellas pharma d.o.o. - levprorelin - prašek in vehikel za raztopino za injiciranje - levprorelin 6,96 mg / 1 brizga - levprorelin

Európai Unió - szlovén - EMA (European Medicines Agency)

accord healthcare s.l.u. - relugolix - prostatične neoplazme - endokrini terapija - orgovyx is indicated for the treatment of adult patients with advanced hormone-sensitive prostate cancer.

Európai Unió - szlovén - EMA (European Medicines Agency)

virbac s.a. - osateron acetat - urološki - psi - zdravljenje benigne hipertrofije prostate (bph) pri moških pseh.

Európai Unió - szlovén - EMA (European Medicines Agency)

krka, d.d., novo mesto - abirateron acetat - prostatične neoplazme - endokrini terapija - abiraterone krka is indicated with prednisone or prednisolone for:the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer (mhspc) in adult men in combination with androgen deprivation therapy (adt) (see section 5. 1)the treatment of metastatic castration resistant prostate cancer (mcrpc) in adult men who are asymptomatic or mildly symptomatic after failure of androgen deprivation therapy in whom chemotherapy is not yet clinically indicated (see section 5. 1)the treatment of mcrpc in adult men whose disease has progressed on or after a docetaxel-based chemotherapy regimen.

Európai Unió - szlovén - EMA (European Medicines Agency)

n.v. organon - korifolitropin alfa - reproductive techniques, assisted; ovulation induction; investigative techniques - spolni hormoni in zdravila genitalni sistem, - controlled ovarian stimulation (cos) in combination with a gnrh antagonist for the development of multiple follicles in women participating in an assisted reproductive technology (art) program. elonva is indicated for the treatment of adolescent males (14 to less than 18 years and older) with hypogonadotropic hypogonadism, in combination with human chorionic gonadotropin (hcg).